ASH 2015 - Multiple Myeloma

Potential Side Effects and How to Treat

Jack Aiello shares his experience on orals,and the significance of informing patients of the side effects and mitigating them.

Oral Treatment vs. Others

Jack Aiello offers insights into oral medications as opposed to other treatments and why orals can be more challenging due to potential patient issues.

Sharing Markers with Patients

Jack Aiello talks about the importance of providers helping patients understand the value of markers and how that can positively affect the latter's compliance.

Adding to the Therapy Arsenal

Jack Aiello enthusiastically discusses the additions of newer medicines that were FDA approved in 2015, and why patients need to be aware of them.

Educating Myeloma Patients

Gary Peterson believes patients should be educated to understand things like chemo brain and the financial aspects of cancer treatment, and that they both play huge roles in a lack of medication adherence.

Understanding the Financial Aspects Associated with Treatment

As the typical myeloma patient population is older, Gary Peterson addresses the financial challenges for seniors and paying for medications.

The Patient Perspective: New Multiple Myeloma Drugs

Gary Peterson talks about what the addition of new myeloma medicines means to patients.

New Myeloma Medicines

Yelak Biru offers his feedback on the new medications that were approved in 2015, and the importance of knowing how these medicines will be used and which types of patients will be treated with them.

Creating an Open Dialogue with Providers

Yelak Biru points out the importance of patients being able to set up an ongoing dialogue with their providers outside of the formal appointment settings.

Oral vs. Physician-Administered Drugs

Yelak Biru identifies similarities and differences between oral and physician-administered drugs, noting that patient-provider relationships are even more crucial when dealing with an oral drug regimen.